Evotec

Evotec published final H1 figures that match the preliminary July numbers: half-year revenue €300.1m, adjusted group EBITDA -€42.7m. The full-year outlook remains €570–610m in revenue and an EBITDA of -€70m to -€105m. Half-year revenue is 19.2% below the prior year, and the biologics business contracted 29.3% due to Sandoz effects. Two downward revisions to guidance have caused the share price to fall by more than one-third year-to-date, although the core business could be evaluated in a more differentiated way. » More on finanzen.net

Evotec lowered its 2026 revenue forecast from €700–780m to €570–610m and now expects an adjusted EBITDA loss of €70–105m after H1 revenue growth weakened and the EBITDA loss widened. In response, it launched the restructuring program “Horizon,” consolidating to ten sites and targeting about €75m in annual savings by end-2027; CFO Claire Hinshelwood is driving cost discipline. The analyst picture is mixed: the average consensus is €4.90 (3× buy / 5× hold), but recent July reports frequently cut ratings to “hold” and reduced price targets. A floor in the share price depends on visible H2 progress on “Horizon,” realized savings and new partnership deals that could cushion the revenue decline. » More on de.investing.com

Evotec shares rise about 6% to €3.63, recovering from a ten-year low after a roughly 29% drop following a drastic profit warning. The company cut its revenue forecast to €570–610 million and now expects adjusted EBITDA of −€70 to −€105 million, driven by deferred milestone payments and delayed partnerships. Several analysts lowered price targets to €3.50–4.00, with only RBC keeping a €10.00 target; the consensus is €4.90. Evotec still has a buffer with around €465.6 million in liquidity and core growth of over 28% in H1, but the audited half-year report on August 13 is seen as the next test. » More on de.investing.com